Science & Medicine

An old friend springs to our defense against a new enemy.

Last week, without comment, I sent one of our MPN Interferon gurus a link to a Chinese story about Cuban use of Interferon Alpha 2B to treat COVID-19 Honestly, I had no opinion, no basis to judge one way or another whether or not this was a ray of hope. .

Could interferon, the old immunity-boosting, virus-busting friend of our MPN community, have any real role in stopping the global rampages of this predatory plague that has ground industry to a halt, confined us to quarters, and mows us down with sickness and death?

And then early this morning, Wednesday, April 1. on the BBC World Service News, an 18 minute segment on an inhalant version of Interferon Alpha 1B that had already passed the initial clinical trial test stages with good results. The story includes an interview with the Synairgen CEO.

With so many rumors and false hopes flying around, I hesitate to present anything conclusive, so here’s the raw data…. The story, the podcast, the Google search… Dig in and see what you think..and share your thoughts.

(It might be a welcome relief from the endless Netflix binge sessions, naps, and trips to the fridge that help fill in this quarantined era.)

Go here for the BBC Story/Podcast

Here’s the original clip I sent to the good doctor, the Wizard of Weill-Cornell:


Cuba’s Interferon Alpha 2B

And finally, first Google results on the the company, Synairgen and the clinical trials.

Spring 2020 available


Take break.  Forget the Election Primary Season, Brexit, and the Coronavirus.

It’s time to kick back and pick up your copy of The Spring, 2020 MPNforum.  Now available.

  • First in-human clinical trial: Giant leap toward MPN therapy. Genetically engineered cells found safe and durable in blood cancer treatment….
  • Reporting on science and the darker side of the MPN industry after MPNforum…
  • From the Archives, Best of…:Dr. Arch, Harvey Gould, Imetelstat, Dr. Hans Hasselbalch, Terri Libenson, Shaoguang Li.
  • PLUS… The List of Hematologists, MPNclinics, and all the rest of the good stuff…

It’s all yours at  Enjoy (and don;t forget to wash your hands).

Corruption: The Worst Thing We Face…Gene Editing: Our Best Hope.

.Fedratinib was dead in the water…suspended by the FDA, aborted by its sponsor, Sanofi.

.This year, bought by Celgene, Fedratinib, renamed Inrebic, was approved by the FDA.  Last month Bristol-Myers Squibb acquired Celgene for $74 BILLION.  Notte: Incyte’s Jakafi raked in $1.4 billion in annual MPN sales last year.

.It’s all part of the MPN Gold Rush that transformed our rare disease into rock star status. And has corrupted our MPN life.

.Read about it the January , 2020 MPNforum…PLUS Good news: Gene editing closes in on blood cancers.  The upgraded MAGIC MPN symptom calculator; And a fresh update of the List of Patient-recommended Hematologists.

.Available now at:

. Happy holidays,


The MPN Gold Rush

Your pre-publication copy is now available.






Just a couple of years ago Sanofi’s fedratinib – a Jakafi competitor — was dead in the water. Its Phase 3 clinical trial was suspended by the FDA. The trial was aborted by its sponsor, Sanofi.

This year, in the hands of Celgene, the drug was revived as inrebic and approved by the FDA. Last month Bristol-Myers Squibb acquired Celgene for $74 Billion.

It’s part of the MPN Gold Rush that transformed our rare disease into rock star status with Incyte’s Jakafi rocketing to $1.4 billion in MF annual sales.  And it complicates our MPN lives.

It all started with a tube of skin cream…

That’s the lead story of the January 2020 MPNforum…PLUS Good news as gene editing closes in on blood cancers. AND a fresh update of the List of Patient-recommended Hematologists.

Your MPNforum pre-publication copy is available now at


You have the weekend to look it over before publication so do please shoot any corrections or comments to us:


Happy holidays,






The MAGIC of good people working together.

We owe a debt of gratitude to 18 people, the MS3T all volunteer medical taskforce.

Sometimes, well below the radar, there are good people working for the benefit of MPN patients without reward, publicity, or even acknowledgement.

For nearly two years, work has been progressing on MAGIC, a simple graphic calculator to assess the risk status of myelofibrosis patients. This is a critically needed tool in an environment where most MPN patients are not treated by specialists and where the outcome of certain procedures depends on timing.

The MS3T Taskforce– contributing to and reviewing the original stem cell transplant timing tool–includes four hematologists (DoctorsClaire Harrison, Ruben Mesa, Richard Silver, Srdan Verstovsek) four transplant specialists (Doctors Koen Van Besien, Nicolaus Kroeger, Jeanne Palmer,Uday Popat) a hematopathologist (Dr. Attilio Orazi), the Scientific Director of CIBMT( Dr. Wael Saber), three MPN patients, Chris Harper, Beatrice Larroque, Marty Prager; and four patient advocates, Ann Brazeau, Ann Haehn, Barbara Van Husen, Michelle Woerhle.

MAGIC – the Myelofibrosis Assessment Graphic Internet Calculator— will soon find a permanent home with the original project sponsor, MPN Research Foundation. But you can preview MAGIC right now at

Take it for a test drive and let your MPN friends know there’s now a quick. validated means to help us work with our docs in making therapeutic decisions.

Thank you…and thank you, MS3T,

Zhenya Senyak, Project Director

Here is your Advance Copy of the July-August 2019 MPNforum Magazine.
General publication is tomorrow,so if you have any questions or comments please let me know.
 (Until tomorrow afternoon, the URL is:

Summertime Reading – MPforum AVAILABLE NOW


Here are the 15 Top MPN mutations and how they affect us

Along with a free mutation reference manual …

AND The RESULTS: 1068 MPN patients and Genomic Testing..

Plus the updated LIST of patient recommended hematologists,.

It’s all at

%d bloggers like this: